株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

癌治療におけるNDDS市場 - 世界の業界分析、規模、シェア、成長、動向と将来予測

NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

発行 Transparency Market Research 商品コード 318436
出版日 ページ情報 英文 81 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
癌治療におけるNDDS市場 - 世界の業界分析、規模、シェア、成長、動向と将来予測 NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
出版日: 2014年10月28日 ページ情報: 英文 81 Pages
概要

ドラッグデリバリーシステムとしてナノ粒子が有望な技術として登場し、様々な種類の癌を患う患者の治療に役立てられています。その小ささゆえ、ナノ粒子には独自の物理化学的および生物学的特性があり、従来のドラッグデリバリーの多くが抱えていた生体内分布の不備、水溶性の低さなどの問題を解決しています。

当レポートでは、癌治療におけるNDDS(新規ドラッグデリバリーシステム)市場の現状と将来的見通しについて調査し、セグメント別の動向、および地域別動向などをまとめています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 市場概要

  • イントロダクション
  • 世界の罹患率および発症率データ
  • 癌治療におけるNDDSの適応現状
    • 肝癌
    • 膵臓癌
    • 胆管癌
    • 結腸直腸癌
    • 動静脈奇形
    • 血管過剰悪性腫瘍
    • 動脈瘤
  • 市場促進因子
    • 様々な癌の発症率上昇
    • 他の治療やドラッグデリバリーシステムを凌ぐ塞栓剤およびナノ粒子の臨床的メリット
    • 新たな革新的治療の開発につながる技術的進歩
    • NDDSの治療適応の拡大
  • 市場阻害因子
    • NDDSに伴う治療費の高騰
    • 厳しい法的経路と新製品開発のコストの高さ
  • 機会
    • ナノが可能とするドラッグデリバリーシステムの開発への投資
  • 商品化に向けた法規制経路
    • 米国
    • EU
  • イベント影響分析
  • 市場の魅力度分析

第4章 世界の塞栓粒子市場収益:タイプ別

  • 概要
  • 現在の技術
    • 薬剤溶出技術
    • 他の技術
  • 新興技術
    • 選択的内照射療法/放射線塞栓療法
    • ホルミウムミクロスフェア
  • 近年のイベント
  • 競合分析

第5章 世界の塞栓液市場収益:ブランド別

  • 概要
  • 近年の発展動向
  • 競合分析

第6章 世界のナノ粒子市場収益

  • 概要
  • 競合分析

第7章 癌治療におけるNDDS市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第8章 提言

目次

This study on novel drug delivery systems (NDDS) in cancer therapy comprises study of technologies such as embolization devices, liquid embolics and nanoparticles that offer unique approaches in cancer remedy. Several embolic agents are used by interventional radiologists for the selective occlusion of arteries supplying blood to tumors. The selection of an embolic agent depends on various factors including size of the vessel to be embolized, desired clinical outcome, duration of the vessel to be occluded, and also the intrinsic properties and behavior of the embolic agent. Nanoparticles as drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. Owing to their small size, nanoparticles exhibit unique physicochemical and biological properties, and thus help in overcoming several limitations such as poor bio-distribution, non-specific drug delivery, low therapeutic indices, and lack of water solubility which are mostly associated with conventional drug delivery.

This report studies the global market for NDDS in cancer therapy encompassing three major technologies: embolization particles, liquid embolics and nanoparticles. Each of these technologies has been analyzed in detail from product analysis, market trends, recent developments, future outlook and opportunities, to the competitive landscape. The report provides market size in terms of USD million for each technology for the period 2012 to 2020, considering the macro and micro environmental factors. In addition, the compounded annual growth rate (CAGR) of the overall NDDS in cancer therapy market and the segments has also been provided in the report for the forecast period 2014 to 2020, considering 2012 and 2013 as the base years. This report includes an elaborate executive summary, which covers a market snapshot representing key findings from the study.

Geographically, the NDDS in cancer therapy market has been classified into four regions namely, North America, Europe, Asia Pacific and Rest of the World (RoW). The market size and forecast for each of these regions along with CAGR for the forecast period from 2014 to 2020 have also been provided in the report. A detailed qualitative analysis of the major factors determining market dynamics such as drivers, restraints and opportunities, along with the market attractiveness analysis are discussed in the market overview section of the NDDS in cancer therapy market report. A section describing the U.S. and EU regulatory pathways has also been included. The study on NDDS in cancer therapy suggests a list of recommendations for new companies willing to enter the market and for existing companies to accentuate shares, which is likely to help in the decision-making process. ANSOFF matrix analysis has also been provided for the key players in this market. The competitive landscape section has been provided for each technology separately and presents the market revenue share of key players in terms of percentage for the year 2013. The market share analysis of key players involved the study of company product portfolio, sales revenue, and geographical presence along with market developments such as new product launch, brand recall, regulatory approvals, etc.

The study is a robust combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interaction via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases for patents, clinical trials, demographics, disease incidence/prevalence, etc. The key players operating in the NDDS in cancer therapy market are Advanced Medical Isotope Corporation, Bind Therapeutics, Boston Scientific Corporation, BTG plc, CeloNova BioSciences, Inc., Cook Medical, Inc., Cospheric LLC, Covidien, plc, Eckert & Ziegler BEBIG, EmboMedics, Inc., Kobo Products, Inc., Merit Medical Systems, Inc., Mo-Sci Corporation, Nanobiotix, Polysciences, Inc., Sirtex Medical, Inc. and Terumo Medical Corporation.

The global NDDS in cancer therapy market is segmented as follows:

NDDS in Cancer Therapy Market, by Technology

  • Embolization Particles
    • Current Technologies
      • Drug Eluting Beads
      • Others (PVA particles, microspheres, gelatin-based)
    • Emerging Technologies
      • Selective Internal Radiation Therapy (SIRT)
      • TheraSphere
      • SIR-Spheres
      • Holmium-based Microspheres
    • Liquid Embolics
      • Onyx (LES and HD-500)
      • TRUFILL nBCA LES
    • Nanoparticles

NDDS in Cancer Therapy Market, by Geography

  • North America
    • Embolization Particles
    • Liquid Embolics
    • Nanoparticles
  • Europe
    • Embolization Particles
    • Liquid Embolics
    • Nanoparticles
  • Asia Pacific
    • Embolization Particles
    • Liquid Embolics
    • Nanoparticles
  • Rest of the World (RoW)
    • Embolization Particles
    • Liquid Embolics
    • Nanoparticles

Table of Contents

Chapter 1 Preface

  • 1.1 Report Description
  • 1.2 Market Segmentation
  • 1.3 Research Methodology
    • 1.3.1 Sources
      • 1.3.1.1 Secondary Research
      • 1.3.1.2 Primary Research
    • 1.3.2 Assumptions and Limitations
    • 1.3.3 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot: Global NDDS in Cancer Therapy Market (2013 & 2020)
  • 2.2 Global NDDS in Cancer Therapy Market, by Technology, 2013 (USD Million)
  • 2.3 Comparative Analysis: Global NDDS in Cancer Therapy Market Revenue, by Geography, 2013 & 2020 (Value %)

Chapter 3 Market Overview

  • 3.1 Introduction
  • 3.2 Global Prevalence and Incidence Data
    • 3.2.1 Global Historical Prevalence (Number of Cases), by Major Cancer Type (2008 - 2012)
    • 3.2.2 Global Prevalence Forecast (Number of Cases), by Major Cancer Type (2013 - 2020)
    • 3.2.3 Global Historical Incidence (Number of Cases), by Major Cancer Type (2008 - 2012)
    • 3.2.4 Global Incidence Forecast (Number of Cases), by Major Cancer Type (2013 - 2020)
  • 3.3 Current Major Indications for NDDS in Cancer Therapy
    • 3.3.1 Liver Cancer
    • 3.3.2 Pancreatic Cancer
    • 3.3.3 Bile Duct Cancer
    • 3.3.4 Colorectal Cancer
    • 3.3.5 Arteriovenous Malformations
    • 3.3.6 Hypervascular Malignant Tumors
    • 3.3.7 Aneurysms
  • 3.4 Drivers
    • 3.4.1 Growing incidence of various types of cancer
    • 3.4.2 Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems
    • 3.4.3 Technological advances leading to the development of new and innovative therapy
    • 3.4.4 Expanding therapeutic indications of NDDS
  • 3.5 Restraints
    • 3.5.1 High treatment cost associated with NDDS
    • 3.5.2 Strict regulatory pathway and high cost associated with new product development
  • 3.6 Opportunities
    • 3.6.1 Investing in the development of nano-enabled drug delivery systems
  • 3.7 Regulatory Pathway to Commercialization
    • 3.7.1 U.S. Food and Drug Administration (FDA)
      • 3.7.1.1 Major Steps: U.S. FDA Regulatory Approval Pathway
    • 3.7.2 EU (CE Marking)
      • 3.7.2.1 Major Steps: CE Marking Regulatory Approval Pathway
  • 3.8 Event Impact Analysis
  • 3.9 Market Attractiveness Analysis: Global NDDS in Cancer Therapy Market, by Geography

Chapter 4 Global Embolization Particles Market Revenue, by Type

  • 4.1 Overview
    • 4.1.1 Global Embolization Particles Market Revenue, by Type, 2012 - 2020 (USD Million)
  • 4.2 Current Technologies
    • 4.2.1 Drug Eluting Beads
      • 4.2.1.1 Global Drug Eluting Beads Market Revenue, 2012 - 2020 (USD Million)
    • 4.2.2 Other Current Technologies
      • 4.2.2.1 Global Other Current Technologies Market Revenue, 2012 - 2020 (USD Million)
      • 4.2.2.2 Polyvinyl Alcohol (PVA) Particles
      • 4.2.2.3 Microspheres
      • 4.2.2.4 Gelatin-based Embolization Devices
  • 4.3 Emerging Technologies
    • 4.3.1 Selective Internal Radiation Therapy (SIRT) / Radioembolization
      • 4.3.1.1 Global SIRT/ Radioembolization Market Revenue, 2012 - 2020 (USD Million)
      • 4.3.1.2 SIR-Spheres Microspheres
        • 4.3.1.2.1 Global SIR-Spheres Market Revenue, 2012 - 2020 (USD Million)
      • 4.3.1.3 TheraSphere
        • 4.3.1.3.1 Global TheraSphere Market Revenue, 2012 - 2020 (USD Million)
    • 4.3.2 Holmium-based Microspheres
  • 4.4 Recent Events
  • 4.5 Competitive Analysis
    • 4.5.1 Market Share Analysis: Embolization Particles, by Key Players, 2013 (Value %)

Chapter 5 Global Liquid Embolics Market Revenue, by Brand

  • 5.1 Overview
    • 5.1.1 Global Liquid Embolics Market Revenue, by Brand, 2012 - 2020 (USD Million)
    • 5.1.2 Onyx
      • 5.1.2.1 Global Onyx Devices Market Revenue, 2012 - 2020 (USD Million)
    • 5.1.3 TRUFILL n Butyl Cyano Acrylate (nBCA) Liquid Embolic System
      • 5.1.3.1 Global TRUFILL nBCA Liquid Embolic Systems Market Revenue, 2012 - 2020 (USD Million)
  • 5.2 Recent Developments
  • 5.3 Competitive Analysis
    • 5.3.1 Market Share Analysis: Liquid Embolics, by Key Players, 2013 (Value %)

Chapter 6 Global Nanoparticles Market Revenue

  • 6.1 Overview
    • 6.1.1 Global Nano-enabled Drug Delivery Systems in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
    • 6.1.2 Approved Nano-enabled Drug Delivery Systems for Cancer Treatment
    • 6.1.3 Nano-enabled Drug Delivery Systems in Cancer Treatment Under Clinical Investigation
    • 6.1.4 Emerging Technologies and Treatments
      • 6.1.4.1 Nanocarriers
  • 6.2 Competitive Analysis
    • 6.2.1 Market Share Analysis: Nanoparticles, by Key Players, 2013 (Value %)

Chapter 7 Global NDDS in Cancer Therapy Market, by Geography

  • 7.1 Overview
    • 7.1.1 Global NDDS in Cancer Therapy Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • 7.2 North America
    • 7.2.1 North America NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
    • 7.2.2 North America NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
    • 7.3.2 Europe NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
    • 7.4.2 Asia Pacific NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
  • 7.5 Rest of the World
    • 7.5.1 Rest of the World NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
    • 7.5.2 Rest of the World NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)

Chapter 8 Recommendations

  • 8.1 Strategies for Success
  • 8.2 ANSOFF Matrix

List of Figures

  • FIG. 1 Market Segmentation: NDDS in Cancer Therapy
  • FIG. 2 Global NDDS in Cancer Therapy Market, by Technology, 2013 (USD Million)
  • FIG. 3 Comparative Analysis: Global NDDS in Cancer Therapy Market Revenue, by Geography, 2013 & 2020 (Value %)
  • FIG. 4 Global Historical Prevalence (Number of Cases), by Major Cancer Type (2008 - 2012)
  • FIG. 5 Global Prevalence Forecast (Number of Cases), by Major Cancer Type (2013 - 2020)
  • FIG. 6 Global Historical Incidence (Number of Cases), by Major Cancer Type (2008 - 2012)
  • FIG. 7 Global Incidence Forecast (Number of Cases), by Major Cancer Type (2013 - 2020)
  • FIG. 8 Major Steps: U.S. FDA Regulatory Approval Pathway
  • FIG. 9 Major Steps: CE Marking Regulatory Approval Pathway
  • FIG. 10 Market Attractiveness Analysis: Global NDDS in Cancer Therapy Market, by Geography
  • FIG. 11 Global Drug Eluting Beads Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 12 Global Other Current Technologies Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 13 Global SIRT/ Radioembolization Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 14 Global SIR-Spheres Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 15 Global TheraSphere Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 16 Market Share Analysis: Embolization Particles, by Key Players, 2013 (Value %)
  • FIG. 17 Global Onyx Devices Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 18 Global TRUFILL nBCA Liquid Embolic Systems Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 19 Market Share Analysis: Liquid Embolics, by Key Players, 2013 (Value %)
  • FIG. 20 Global Nano-enabled Drug Delivery Systems in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 21 Market Share Analysis: Nanoparticles, by Key Players, 2013 (Value %)
  • FIG. 22 North America NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 23 Europe NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 24 Asia Pacific NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 25 Rest of the World NDDS in Cancer Therapy Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 26 ANSOFF Matrix: NDDS in Cancer Therapy Market

List of Tables

  • TABLE 1 List of Abbreviations
  • TABLE 2 Market Snapshot: Global NDDS in Cancer Therapy Market (2013 & 2020)
  • TABLE 3 Event Impact Analysis: Global NDDS in Cancer Therapy Market
  • TABLE 4 Global Embolization Particles Market Revenue, by Type, 2012 - 2020 (USD Million)
  • TABLE 5 Global Liquid Embolics Market Revenue (Forecast), by Brand, 2012 - 2020 (USD Million)
  • TABLE 6 Approved Nano-enabled Drug Delivery Systems for Cancer Treatment
  • TABLE 7 Nano-enabled Drug Delivery Systems in Cancer Treatment Under Clinical Investigation
  • TABLE 8 Global NDDS in Cancer Therapy Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • TABLE 9 North America NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
  • TABLE 10 Europe NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
  • TABLE 11 Asia Pacific NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
  • TABLE 12 Rest of the World NDDS in Cancer Therapy Market Revenue, by Technology, 2012 - 2020 (USD Million)
Back to Top